about
Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?An essential signal peptide peptidase identified in an RNAi screen of serine peptidases of Trypanosoma bruceiAngelica dahurica Extracts Improve Glucose Tolerance through the Activation of GPR119Teneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetesEmerging gliptins for type 2 diabetes.The clinical development program of lixisenatide: a once-daily glucagon-like Peptide-1 receptor agonist.Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira).DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice.Blood pressure and cardiovascular effects of new and emerging antidiabetic agents.Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats.Linagliptin: A thorough Characterization beyond Its Clinical EfficacyThe heart as an endocrine organ.Antidiabetic agents: past, present and future.Mechanisms underlying weight loss after bariatric surgery.Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.Potential side effects to GLP-1 agonists: understanding their safety and tolerability.Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes.DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure.The Dietary Furocoumarin Imperatorin Increases Plasma GLP-1 Levels in Type 1-Like Diabetic Rats.Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.Proceedings of the 2017 ASPEN Research Workshop-Gastric Bypass: Role of the Gut.Alogliptin: a new dipeptidyl peptidase-4 inhibitor with potential anti-atherogenic properties.The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study.
P2860
Q27015789-1B992E67-3A01-4794-9F96-A64670E34203Q28545105-D3B75C4C-85E6-4EEB-B098-6A5BAD8AD6EBQ28552543-555C2B21-2BB0-4CAE-B0BD-EDA568D04AD5Q33688333-D27D40EC-FF4F-440A-A255-A3EBA4BD23F8Q34347884-9E25BF93-F7D4-4C88-9294-4FFD2A6B8D6BQ34726309-780890B2-6FE4-4D4D-BC5E-48FD8FEE1DD3Q35666228-2BB2BD3C-BCC5-46A5-8ADA-1C52D991A15BQ35690114-7A9C7001-A32A-43AB-9C89-D1BF3A585F4BQ36069685-A6107873-10ED-4A38-AB2C-6D7E094FDB0CQ36229592-1C7DC5C3-D31C-4A6E-A6C8-0D7F48340FC3Q36636639-403B835F-8395-45E3-BCB3-30E08D3753E1Q37703738-C0FA242E-B53F-4AC1-9882-CC13EB96BB2AQ38089737-3ACA3334-5C23-400F-8DCF-45340A09A33CQ38120144-B126425F-2808-4EF5-B78C-050495AE60E4Q38167010-BC12AB90-2F2E-43F8-9BDD-4353019277BBQ38286444-9124D4BD-C68A-46A7-9101-0D48FC2748B3Q42876331-A165FC0F-21B7-4354-9657-ABB510F6D022Q43054868-2041933F-64B8-4A97-B5C5-BC64E1E9C0A6Q47113797-AF7D60D4-F198-4A80-B6C0-D023D4540F49Q47951604-1CFFC2DE-FD08-4F0B-95E4-2CBCC7891ADFQ50005567-DAE8669A-800A-4851-B0AF-26AF30527C7BQ51316002-726DBF0A-3EE6-4AFC-8E1E-FF3FC845B894Q54580077-D5608DFE-21F4-4D25-8E4E-B06AB3971FAB
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Recent advances in incretin-based therapies.
@en
type
label
Recent advances in incretin-based therapies.
@en
prefLabel
Recent advances in incretin-based therapies.
@en
P2860
P1476
Recent advances in incretin-based therapies.
@en
P2093
David Russell-Jones
Stephen Gough
P2860
P304
P356
10.1111/J.1365-2265.2012.04483.X
P577
2012-10-01T00:00:00Z